Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Erectile Dysfunction 1

Interventions

zanubrutinib 1venetoclax 1talabostat 1ibrutinib 1acalabrutinib 1Tablets 1Rituximab 1PT-100 dipeptide 1Clofarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Leukemia, Lymphocytic, Chronic, B-Cell × Tablets × Clear all
NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡